The idea that 'sugar feeds cancer' should be dropped: sugar feeds every cell (and microbe), so cancer patients need not fear sugar.
Original statement
السكر يا بابا غذا كل حاجه البكتيريا بتاكل سكر
verbatim according to source. Translation by the project; the Arabic wording is authoritative.
Translation
The idea that 'sugar feeds cancer' should be dropped: sugar feeds every cell (and microbe), so cancer patients need not fear sugar.
Origin
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- السرطان ١ (Open source)
- Published
- 26 January 2025
- Timestamp
- 0:22:03 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; spelling errors of the machine transcript are kept verbatim; wording may deviate from the spoken words.
- Population concerned
Cancer patients
- Geographic restriction by Elawady
none found
Scientific assessment
Unclear / insufficient evidence – The data do not allow an assessment either way.
Certainty of evidence: low – Further research is likely to change the assessment considerably.
1. What was claimed?
Sugar does not specifically feed cancer; no need to restrict it in cancer.
2. What is demonstrably correct?
All cells use glucose and blood glucose is regulated; the slogan 'sugar feeds cancer' oversimplifies, and restricting all carbohydrate is not an established cancer treatment.
3. What is wrong or exaggerated?
High sugar intake is associated with weight gain (moderate-quality evidence) and, with low-quality evidence, with some cancers (e.g., fructose and pancreatic cancer) (I-CAN-07); excess body weight causes about 7.6% of US cancers (I-CAN-02). Elawady's broader pro-sugar positions are reviewed by the sugar_soda team.
4. What remains unclear?
Effect of sugar intake on outcomes in people who already have cancer.
5. Which studies support it?
Partly: the slogan 'sugar feeds cancer' oversimplifies physiology, and no direct evidence was reviewed that dietary sugar speeds tumour growth in patients; the umbrella review rates evidence on sugar and cancer as low quality (I-CAN-07).
6. Which studies contradict it?
I-CAN-07 (mixed), I-CAN-02 (excess weight).
7. What applies to Germany and Europe?
Not region-specific; the same physiology and evidence apply.
8. What is known about Egypt?
Not region-specific; the same physiology and evidence apply.
9. What practical conclusion is appropriate?
Cancer patients' diet should be individualised (e.g., diabetes, weight loss, cachexia) with the oncology/dietetics team.
Assessment details
- Rationale for certainty of evidence
No direct evidence reviewed on dietary sugar and tumour progression in patients; observational data on sugar and cancer incidence are low quality; indirect harms via body weight.
- Source quality
Machine transcript.
- Regional transferability
High.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 26 October 2026 provisional
Scientific evidence in detail
Insufficiently studied – There is too little research to say whether the claim is right or wrong.
Research question: In people with cancer, does dietary sugar intake affect cancer outcomes, and is restricting sugar unnecessary?
Research question in detail (PECO)
- Population
- People with cancer (and general population for incidence)
- Intervention or exposure
- Dietary sugar / sugary drinks / refined carbohydrates
- Comparison
- Lower intake; carbohydrate-restricted diets
- Geographic scope
- universal biology
- Outcomes
- Survival / recurrence
- Cancer incidence
- Body weight
Study results as reported by the authors. Our assessment follows below.
What speaks for the claim?
Ketogenic diet trials in cancer: little proven benefit
Salido-Bueno B et al.. Nutr Bull 2024 · PMID 38923748 · DOI 10.1111/nbu.12693 Meta-analysisabstract checkednewly addedRCT meta-analysis: ketogenic (sugar-restricted) diets did not clearly improve cancer-related outcomes.
- Actual result
- Only glucose fell; no significant change in IGF-1, weight, QoL
- Methodological quality
- moderate
- Relevance
- indirect: no proof that cutting sugar helps patients
- Limitations
- Small, short trials.
US cancer doctors' guideline: exercise helps, diet evidence weak
Ligibel JA et al.. J Clin Oncol 2022 · PMID 35576506 · DOI 10.1200/JCO.22.00687 Guideline / position statementabstract checkednewly addedASCO: evidence for specific diets during treatment very limited.
- Actual result
- Guideline statement
- Methodological quality
- high
- Relevance
- indirect
- Limitations
- Evidence base thin.
What speaks against the claim?
Sugary drinks after breast cancer linked to higher death risk
Farvid MS et al.. Cancer 2021 · PMID 33945630 · DOI 10.1002/cncr.33461 Cohort studyabstract checkednewly addedPost-diagnosis sugary drinks in 8,863 breast cancer survivors (NHS/NHSII).
- Actual result
- BC-specific mortality HR 1.35 (1.12-1.62) for >3 servings/week; dose-response
- Methodological quality
- moderate (large prospective cohort, adjusted for adiposity)
- Relevance
- direct (patients)
- Limitations
- Observational.
Diet after bowel cancer and survival
Chen QY et al.. J Natl Cancer Inst 2025 · PMID 40317134 · DOI 10.1093/jnci/djaf098 Meta-analysisabstract checkednewly addedPost-diagnosis diet in colorectal cancer survivors.
- Actual result
- Refined grains RR 1.55 (1.03-2.33) for all-cause mortality; authors advise avoiding SSB
- Methodological quality
- moderate (meta-analysis of cohorts)
- Relevance
- direct (patients)
- Limitations
- Observational; SSB estimate not in abstract.
Sugary drinks and cancer risk in France
Chazelas E et al.. BMJ 2019 · PMID 31292122 · DOI 10.1136/bmj.l2408 Cohort studyabstract checkednewly addedSugary drinks and cancer incidence (NutriNet-Sante).
- Actual result
- sHR 1.18 per 100 mL/day (1.10-1.27)
- Methodological quality
- moderate
- Relevance
- indirect (incidence)
- Limitations
- Short follow-up.
What does the overall evidence say?
Editorial assessment based on the studies above – not itself a study result.
Which position is better supported?
Both extremes are unsupported: dietary sugar does not selectively 'feed' tumours in a way shown to matter clinically, and no sugar-restricted diet has proven cancer benefit; but high intake of sugary drinks and refined carbohydrates is associated with higher cancer risk and with worse survival after breast and colorectal cancer.
Why some studies weigh more
Post-diagnosis cohort data (I-CAN-127, I-CAN-111) are most direct; RCTs of carbohydrate restriction (I-CAN-104) are small; incidence data are indirect.
Is a causal relationship established? Possible, not established Associations are plausible via weight and insulin, but confounding is likely and RCTs are lacking.
Remaining uncertainty
Effect of sugar intake on progression in specific cancers.
Justified conclusion
The slogan 'sugar feeds cancer' is too simple, but 'no need to watch sugar' is not supported either.
Why do studies seem to disagree?
Not a true conflict: RCTs test strict carbohydrate restriction over weeks, cohorts test habitual sugary drinks and refined grains over years.
Does this depend on the country?
- General biological effects
- Universal human biology; applies in Egypt, Germany and elsewhere.
- Eating habits
- Not decisive for this claim.
- Origin of the food
- Not relevant.
- Contaminants
- Not relevant.
- National production conditions
- Not relevant.
- Legal rules
- Not relevant.
- Actual monitoring data
- Not applicable.
A regional difference that changes the conclusion is not supported by robust data.
Statistical re-check
- CI log-symmetry; dose-response – All symmetric; p-trend .001. recalculated
- CI log-symmetry; multiplicity – Symmetric; refined-grain lower bound 1.03 -> fragile; many exposures tested. recalculated
- CI log-symmetry – Symmetric. recalculated
Certainty of the overall evidence (GRADE, simplified)
- Main outcome
- Sugar intake and outcomes in people with cancer
- Starting level
- low (observational studies)
- Reasons for downgrading
- risk of bias (confounding)
- indirectness (incidence data, refined grains vs sugar)
- imprecision
- Result
- low
Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.
Clinical guidelines and official statements checked
- ASCO: Exercise, Diet, and Weight Management During Cancer Treatment (PMID 35576506) (2022) · Original publication
Exercise recommended during curative treatment; neutropenic diets not recommended; evidence for other dietary and weight-loss interventions during treatment very limited (abstract). - WCRF/AICR: Our Cancer Prevention Recommendations (2018 (accessed 2026)) · Original publication
Ten recommendations including eat wholegrains, vegetables, fruit and beans; limit fast foods, red and processed meat, sugar-sweetened drinks and alcohol; do not use supplements for cancer prevention; follow the recommendations after a cancer diagnosis if you can.
Search strategy
Documented literature searches for this review (search strings in the original database syntax).
| Database | Date | Search | Looking for | Hits | Included |
|---|---|---|---|---|---|
| Europe PMC | 26 October 2026 | (sugar OR "added sugar" OR "sugar-sweetened" OR fructose OR "glycemic load") AND ("cancer survivors" OR "cancer recurrence" OR "cancer-specific mortality" OR "after diagnosis") AND (cohort OR prospective OR "meta-analysis") | both directions | 6473 | |
| Europe PMC | 26 October 2026 | ("sugary drinks" OR "sugar-sweetened beverages" OR "sugary drink") AND (cancer) AND (risk OR incidence) AND (TITLE:cancer) AND (PUB_TYPE:"Meta-Analysis" OR TITLE:"cohort" OR TITLE:"prospective") | contradicting evidence | 197 | |
| Europe PMC | 26 October 2026 | TITLE:"Sugary drink consumption and risk of cancer" | contradicting evidence | 1 | |
| Europe PMC | 26 October 2026 | (Tayebat OR Tayibat OR Elawady OR "El-Awady diet" OR "Al-Awady") | both directions | 377 | |
| PubMed | 26 October 2026 | (sugar[ti] OR carbohydrate[ti] OR "glycemic"[ti]) AND (cancer survivors[tiab] OR "after diagnosis"[tiab]) AND (survival[tiab] OR recurrence[tiab]) | supporting evidence | 11 |
Open questions
RCTs of sugar reduction after diagnosis.
How deeply was this checked?
9 linked studies: 0 checked in full text (0 of them with a structured risk-of-bias assessment), 9 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.
Last scientific review: 26 October 2026
History of the verdict
- 25 October 2026 · Phase 1 · Initial assessment: Unclear / insufficient evidence (low)
- 26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: Unclear / insufficient evidence (low)
Unchanged; new evidence points in both directions (no proven benefit of restriction; observational harm signals).
New sources: I-CAN-103 I-CAN-104 I-CAN-105 I-CAN-111 I-CAN-112 I-CAN-125 I-CAN-127
In plain language
Dr. Diaa said the idea that sugar 'feeds cancer' is wrong because sugar feeds all cells. It is true that the slogan is too simple. But eating a lot of sugar promotes weight gain, and excess weight raises the risk of several cancers. How much sugar a cancer patient should eat depends on the person and should be decided with the care team.
Studies on this claim
Studies supporting the claim (0)
No studies in this group.
Studies contradicting or limiting the claim (2)
-
Sugary drinks and cancer risk in France
Chazelas E et al.. BMJ 2019 · PMID 31292122 · DOI 10.1136/bmj.l2408Cohort studyindependent cross-checkabstract checkedEach extra 100 mL of sugary drinks per day was linked to 18% higher cancer risk.
Sugary drinks associated with higher cancer incidence
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Sugary drinks and cancer.
- How was the study done?
Prospective cohort.
- How many people, animals or samples were studied?
101,257 adults.
- What was actually found?
Higher risk with sugary drinks.
- How large was the observed effect?
sHR 1.18 per 100 mL/d.
- What do the results mean in everyday life?
Limiting sugary drinks is sensible.
- What are the study's limitations?
Observational; short follow-up.
- What does it say about Elawady's specific claim?
Contradicts 'no need to fear sugar' for prevention.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Effects in patients already diagnosed.
-
Sugary drinks after breast cancer linked to higher death risk
Farvid MS et al.. Cancer 2021 · PMID 33945630 · DOI 10.1002/cncr.33461Cohort studyindependent cross-checkabstract checked★ key studyWomen who drank sugary drinks after a breast cancer diagnosis had a 31-35% higher risk of dying from breast cancer.
Post-diagnosis SSB linked to 31-35% higher breast cancer mortality
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
SSB after breast cancer and death.
- How was the study done?
Prospective cohort.
- How many people, animals or samples were studied?
8,863 survivors.
- What was actually found?
Higher mortality with SSB; not with diet drinks.
- How large was the observed effect?
HR 1.35 (>3 servings/week).
- What do the results mean in everyday life?
Limiting sugary drinks after cancer is sensible.
- What are the study's limitations?
Observational.
- What does it say about Elawady's specific claim?
Contradicts the claim.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Cause and effect.
No study in this group is marked as key.
Studies with mixed or unclear results (7)
-
High sugar intake is linked to many health problems, weakly to some cancers
Huang Y et al.. BMJ 2023 · PMID 37019448 · DOI 10.1136/bmj-2022-071609Systematic reviewindependent cross-checkabstract checkedEvidence for weight gain is moderate; links with cancers are mostly low quality.
Low-quality associations with some cancers; weight gain
Does the study support the specific claim? Unclear · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Review sugar-health evidence.
- How was the study done?
Umbrella review.
- How many people, animals or samples were studied?
73 meta-analyses.
- What was actually found?
Mostly harmful associations.
- How large was the observed effect?
Fructose +22% pancreatic cancer per 25 g/d (low quality).
- What do the results mean in everyday life?
Limit added sugar.
- What are the study's limitations?
Observational.
- What does it say about Elawady's specific claim?
Does not show sugar 'feeds' tumours.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Effects in cancer patients.
-
Four in ten cancers in the USA are linked to avoidable risk factors, led by smoking
Islami F et al.. CA Cancer J Clin 2024 · PMID 38990124 · DOI 10.3322/caac.21858Risk assessmentindependent cross-checkabstract checked★ key studySmoking accounted for 19% of cancers and 29% of cancer deaths; excess weight and alcohol followed.
Excess body weight is a cancer risk
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Estimate preventable cancers.
- How was the study done?
PAF analysis.
- How many people, animals or samples were studied?
US 2019.
- What was actually found?
40% of cases attributable.
- How large was the observed effect?
Smoking 19.3%/28.5%.
- What do the results mean in everyday life?
Not smoking, healthy weight, less alcohol and a diet with fibre, fruit and vegetables lower risk.
- What are the study's limitations?
Model assumptions.
- What does it say about Elawady's specific claim?
Diet matters but is not the main cause.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
Individual cause.
-
Diet after bowel cancer and survival
Chen QY et al.. J Natl Cancer Inst 2025 · PMID 40317134 · DOI 10.1093/jnci/djaf098Meta-analysisindependent cross-checkabstract checked★ key studyBowel cancer survivors who ate more whole grains, milk and calcium lived longer; more refined grains and high-fat dairy was linked to shorter survival.
Refined grains associated with higher mortality after CRC; authors advise avoiding SSB
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Diet after CRC diagnosis and death.
- How was the study done?
Meta-analysis of cohorts.
- How many people, animals or samples were studied?
CRC survivors.
- What was actually found?
Whole grains, milk, calcium protective; refined grains harmful.
- How large was the observed effect?
e.g. refined grains RR 1.55; milk RR 0.82.
- What do the results mean in everyday life?
What patients eat may matter.
- What are the study's limitations?
Observational.
- What does it say about Elawady's specific claim?
Does not support ignoring sugar or banning dairy.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Cause and effect.
-
Ketogenic diets in cancer patients: some metabolic benefits
Zhang M et al.. Front Nutr 2025 · PMID 40756563 · DOI 10.3389/fnut.2025.1535921Meta-analysisindependent cross-checkabstract checkedKetogenic diets lowered body fat, insulin and glucose and improved some symptoms; survival was not shown to improve.
Carbohydrate restriction lowers glucose/insulin; no evidence of tumour control
Does the study support the specific claim? Partly · Methodological quality: low · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Effect of ketogenic diets in cancer patients.
- How was the study done?
Systematic review and meta-analysis.
- How many people, animals or samples were studied?
Cancer patients in controlled studies.
- What was actually found?
Better metabolic and some quality-of-life measures.
- How large was the observed effect?
Not quantified in abstract.
- What do the results mean in everyday life?
A diet can affect how patients feel and some blood values.
- What are the study's limitations?
Surrogate outcomes; small studies.
- What does it say about Elawady's specific claim?
Does not show that a diet treats cancer.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
That any diet cures or controls cancer.
-
Ketogenic diet trials in cancer: little proven benefit
Salido-Bueno B et al.. Nutr Bull 2024 · PMID 38923748 · DOI 10.1111/nbu.12693Meta-analysisindependent cross-checkabstract checkedIn 7 small randomised trials, a ketogenic diet lowered blood glucose but did not clearly improve other cancer-related measures.
Carbohydrate restriction lowers glucose but no shown benefit on cancer outcomes
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Assess ketogenic diet effects in cancer RCTs.
- How was the study done?
Meta-analysis of RCTs.
- How many people, animals or samples were studied?
8 RCTs of 4-16 weeks.
- What was actually found?
Only glucose fell.
- How large was the observed effect?
Not quantified in abstract.
- What do the results mean in everyday life?
No diet has been shown to treat cancer.
- What are the study's limitations?
Small, short trials.
- What does it say about Elawady's specific claim?
Contradicts diet-as-treatment claims.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
Long-term effects.
-
US cancer doctors' guideline: exercise helps, diet evidence weak
Ligibel JA et al.. J Clin Oncol 2022 · PMID 35576506 · DOI 10.1200/JCO.22.00687Guideline / position statementindependent cross-checkabstract checked★ key studyASCO found that exercise helps during cancer treatment but that evidence for specific diets is very limited.
No diet (including sugar restriction) proven during treatment
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Guide exercise, diet and weight during cancer treatment.
- How was the study done?
Systematic review plus expert panel.
- How many people, animals or samples were studied?
52 reviews and 23 RCTs.
- What was actually found?
Exercise helps; no diet shown to control cancer.
- How large was the observed effect?
Not applicable.
- What do the results mean in everyday life?
Diet can support, not replace, treatment.
- What are the study's limitations?
Few diet trials.
- What does it say about Elawady's specific claim?
Contradicts diet as cancer cure.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Absence of effect for all diets.
-
Ketogenic diet added to chemotherapy for pancreatic cancer: early trial
Jameson GS et al.. Cancer 2026 · PMID 41817106 · DOI 10.1002/cncr.70343Randomised controlled trialindependent cross-checkabstract checked★ key studyIn 32 patients, adding a supervised ketogenic diet to chemotherapy showed a trend toward longer survival that was not statistically confirmed.
Carbohydrate restriction during chemotherapy: unconfirmed trend
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test a ketogenic diet added to chemotherapy.
- How was the study done?
Randomised phase II trial.
- How many people, animals or samples were studied?
32 patients.
- What was actually found?
Trends toward longer PFS/OS.
- How large was the observed effect?
PFS HR 0.53 (0.21-1.37).
- What do the results mean in everyday life?
Diet research in cancer is about adding to treatment, not replacing it.
- What are the study's limitations?
Small; uncertain; COI.
- What does it say about Elawady's specific claim?
Does not support diet instead of treatment.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
Any proven survival benefit.
No study in this group is marked as key.
Regional context
Germany / EU
Not region-specific; the same physiology and evidence apply.
Egypt
Not region-specific; the same physiology and evidence apply.
What applies in my country?
General scientific assessment
Unclear / insufficient evidence The 'sugar feeds cancer' slogan is oversimplified, but high sugar intake is not harmless.
The following areas of food safety are relevant to this statement:
- Additives and processing
Honey, sugar, sweets
Choose a country to see the checked information for it.
Limits: legal rules describe what is allowed, not what every single food contains. Measurement data come from samples and are meaningful only together with their method details.
Country of residence or purchase Compare with another country
References
- Sugary drink consumption and risk of cancer: results from NutriNet-Santé prospective cohort.. Chazelas E et al.. BMJ 2019 · PMID 31292122 · DOI 10.1136/bmj.l2408
- Consumption of sugar-sweetened and artificially sweetened beverages and breast cancer survival.. Farvid MS et al.. Cancer 2021 · PMID 33945630 · DOI 10.1002/cncr.33461
- Dietary sugar consumption and health: umbrella review.. Huang Y et al.. BMJ 2023 · PMID 37019448 · DOI 10.1136/bmj-2022-071609
- Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, 2019.. Islami F et al.. CA Cancer J Clin 2024 · PMID 38990124 · DOI 10.3322/caac.21858
- Postdiagnosis dietary and lifestyle factors and mortality outcomes among colorectal cancer patients: a meta-analysis.. Chen QY et al.. J Natl Cancer Inst 2025 · PMID 40317134 · DOI 10.1093/jnci/djaf098
- Impact of ketogenic diets on cancer patient outcomes: a systematic review and meta-analysis.. Zhang M et al.. Front Nutr 2025 · PMID 40756563 · DOI 10.3389/fnut.2025.1535921
- Effects of ketogenic diets on cancer-related variables: A systematic review and meta-analysis of randomised controlled trials.. Salido-Bueno B et al.. Nutr Bull 2024 · PMID 38923748 · DOI 10.1111/nbu.12693
- Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline.. Ligibel JA et al.. J Clin Oncol 2022 · PMID 35576506 · DOI 10.1200/JCO.22.00687
- A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer.. Jameson GS et al.. Cancer 2026 · PMID 41817106 · DOI 10.1002/cncr.70343